Survodutide: The Dual Glucagon/GLP-1 Agonist Targeting Liver Disease

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Survodutide?

Survodutide (BI 456906) is an investigational peptide therapeutic developed by Boehringer Ingelheim that acts as a dual agonist of the glucagon receptor and the GLP-1 receptor. While several companies are developing multi-receptor incretin-based therapies, survodutide's specific combination of glucagon and GLP-1 receptor agonism (without GIP) positions it distinctly from tirzepatide (GIP/GLP-1) and retatrutide (GIP/GLP-1/glucagon). The inclusion of glucagon receptor activation is particularly relevant for liver disease applications, where glucagon's role in hepatic lipid metabolism may provide differentiated therapeutic benefit.

Property	Detail
Generic Name	Survodutide (BI 456906)
Developer	Boehringer Ingelheim (in collaboration with Zealand Pharma)
Class	Dual glucagon/GLP-1 receptor agonist
Receptor Targets	Glucagon receptor, GLP-1 receptor
Administration	Once-weekly subcutaneous injection
Phase	Phase 3 (obesity and MASH)
Regulatory Status	Investigational; not approved

Mechanism of Action

Survodutide combines two distinct receptor activities that produce complementary metabolic effects:

GLP-1 Receptor Agonism

The GLP-1 component provides glucose-dependent insulin secretion, glucagon suppression (in the postprandial state), gastric emptying delay, and central appetite suppression through hypothalamic signaling, consistent with the well-characterized effects of the GLP-1 receptor agonist class.

Glucagon Receptor Agonism

The glucagon receptor component contributes mechanisms that are particularly relevant for liver disease and energy expenditure:

• Hepatic fat oxidation: Glucagon promotes the oxidation of fatty acids in the liver, directly reducing hepatic fat content. This mechanism is central to survodutide's potential in NASH/MASH, where excessive hepatic fat accumulation drives disease pathology.
• Increased energy expenditure: Glucagon stimulates thermogenesis, increasing resting metabolic rate and potentially offsetting the adaptive reduction in energy expenditure that occurs during weight loss.
• Amino acid metabolism: Glucagon promotes hepatic amino acid catabolism and ureagenesis.

The potential hyperglycemic effect of glucagon receptor activation is counterbalanced by the simultaneous GLP-1 receptor agonism, which enhances insulin secretion and maintains glucose homeostasis. The net clinical effect in trials has been improved glycemic control.

Research Landscape

Phase 2 Obesity Data

A Phase 2 trial in adults with overweight or obesity demonstrated dose-dependent weight loss with survodutide, with mean reductions of up to 14.9% (at the 4.8 mg dose) at 46 weeks. An exploratory higher dose (6.0 mg) showed approximately 18.7% mean weight loss, though with higher rates of gastrointestinal adverse events. These results are competitive with, though not exceeding, the weight loss demonstrated by tirzepatide and retatrutide.

NASH/MASH Research

Where survodutide may most clearly differentiate itself is in liver disease. Phase 2 data in patients with NASH demonstrated significant reductions in liver fat content (as measured by MRI-PDFF), with a substantial proportion of patients achieving resolution of hepatic steatosis. The glucagon-mediated hepatic fat oxidation mechanism provides a direct, liver-targeted effect that may complement the indirect liver benefits of weight loss. This NASH/MASH application is a key strategic focus for Boehringer Ingelheim's development program.

Key Studies

The Phase 2 data published in major medical journals established survodutide's proof of concept in both obesity and NASH. Phase 3 trials are now underway in both indications, with results expected to determine the compound's regulatory path and commercial positioning.

Safety Profile

The safety profile in Phase 2 trials was generally consistent with incretin-based therapies, with gastrointestinal events (nausea, diarrhea, vomiting) being the most common adverse effects. Rates were dose-dependent, and the higher exploratory doses showed more pronounced GI side effects. The glucagon component raises specific monitoring considerations including hepatic transaminase changes and heart rate effects, both of which are being characterized in Phase 3 studies. No unexpected safety signals have been identified.

Comparison to Related Compounds

Survodutide occupies a specific niche in the growing landscape of multi-receptor agonists. Unlike tirzepatide (GIP/GLP-1), survodutide substitutes glucagon for GIP, potentially offering stronger liver-targeted effects. Unlike retatrutide (GIP/GLP-1/glucagon), survodutide omits GIP, which may result in a different metabolic profile. The glucagon/GLP-1 combination is particularly well-suited to NASH/MASH, where hepatic fat reduction is the primary therapeutic goal.

Current Status

Survodutide is in Phase 3 clinical development for both obesity/overweight and NASH/MASH. It has not been approved by any regulatory authority. Boehringer Ingelheim's decision to pursue NASH/MASH as a co-primary indication alongside obesity reflects a strategic differentiation from competitors focused primarily on weight management. If Phase 3 results confirm the Phase 2 signals, survodutide could become one of the first dual agonists approved specifically for metabolic liver disease.